Jeena Sikho Lifecare Limited has formally notified stock exchanges about an upcoming investor and analyst meeting scheduled for March 23, 2026. The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details and Participants

The investor meeting will feature key company representatives including Mr. Manish Grover, Managing Director of the company, and Dr. Ish Sharma. They will engage with various categories of institutional investors during this interaction session.

Institutional Investor Categories

The meeting will include participation from multiple types of institutional investors:

• Mutual Fund representatives
• Insurance Fund managers
• AIF/PMS participants
• Alternative Investment professionals
• Private Equity Fund representatives

Regulatory Compliance and Information Sharing

The company has emphasized its commitment to regulatory compliance by ensuring that no unpublished price sensitive information will be shared during the meeting. This adherence to disclosure norms reflects the company's commitment to maintaining transparency while protecting market integrity.

The meeting schedule remains subject to potential changes due to exigencies that may arise from either the investor side or the company's requirements. Such flexibility is common in corporate investor interactions to accommodate unforeseen circumstances.

Company Background

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself in the alternative healthcare segment. The company's registered office is located in Zirakpur, Punjab, while its corporate office operates from New Delhi. The meeting details have also been made available on the company's official website at www.jeenasikho.com for broader stakeholder access.

Jeena sikho lifecare Limited has announced the publication of significant medical research by its associated medical professionals in international journals. The company informed stock exchanges on February 23, 2026, about the publication of five case studies and one case report that demonstrate its commitment to Ayurvedic research and evidence-based clinical practice.

Research Publications Overview

The medical research has been published in two prestigious journals - the International Journal of Advanced Research (IJAR) and the Journal of Ayurveda and Integrated Medical Sciences (JAIMS). The publications were authored by medical professionals associated with the company, including the Managing Director, senior consultants, and Ayurvedic experts.

Published Research Details

The company has published research covering various therapeutic areas and Ayurvedic treatment methodologies:

Research Focus Areas

The published research covers several critical health conditions and their Ayurvedic management approaches. The studies focus on:

• Metabolic Disorders: Multiple studies address diabetes mellitus type II management through Ayurvedic interventions
• Liver Conditions: Research on fatty liver disease and chronic liver disease treatment using traditional Ayurvedic methods
• Kidney Health: Case report demonstrating reversal of chronic kidney disease through Ayurvedic interventions
• Digestive Disorders: Studies on Udar Vikar treatment using Shodhana and Shamana therapies

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided complete details of all publications along with their respective journal links for transparency and record-keeping purposes.

Company Background

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself as a provider focused on freedom from diseases and drugs through traditional Ayurvedic treatments. The company is headquartered in Punjab with its corporate office in Delhi and maintains its commitment to evidence-based Ayurvedic practice through continuous research and publication activities.